A Phase 2 interventional study of Placebo and ABT-494 in Crohn's Disease, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-27.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Crohn Disease by AbbVie — 6 open to participants now, 14 under way, 6 of them phase 3. Crohn Disease · AbbVie.
Among the 55 studies in Crohn Disease by AbbVie, this one is the 14th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2015, is one of 8 in phase 2, and was the 20th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →6 of the 55 studies in Crohn Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Canada, Israel and 2 more countries
Ages 18–75
AbbVie · Sites in Italy
Ages 18+
AbbVie · Sites in Belgium
Ages 18+
AbbVie · Sites in United States, Austria, Belgium and 30 more countries
Ages 18–75
AbbVie · Sites in United States, Belgium, Bulgaria and 18 more countries
Ages 2–17
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 220 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 220 across the 27 interventional studies, 252 across the 26 observational. Of the 38 that completed or were terminated, 28 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
2 of the studies in Crohn Disease by AbbVie that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 55 studies in Crohn Disease by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the efficacy and safety of multiple doses of ABT-494 in subjects with moderately to severely active Crohn's Disease with a history of inadequate response to or intolerance to Immunomodulators or anti-Tumor Necrosis Factor (TNF) therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Induction Period ABT-494 Twice Daily Medium/High Dose orally dosed twice a day
Drug: ABT-494
Extension Phase ABT-494 High Dose orally dosed twice a day
Drug: ABT-494
Induction Period Placebo orally dosed twice a day
Drug: Placebo
Induction Period ABT-494 Low Dose orally dosed twice a day
Drug: ABT-494
Induction Period ABT-494 Once Daily Medium/High Dose orally dosed once a day
Drug: ABT-494
Extension Phase ABT-494 Low Dose orally dosed twice a day
Drug: ABT-494
Induction Period ABT-494 High Dose orally dosed twice a day
Drug: ABT-494
Induction Period ABT-494 Low/Medium Dose orally dosed twice a day
Drug: ABT-494
Extension Phase ABT-494 Medium Dose orally dosed twice a day
Drug: ABT-494
Oral Dosing
Oral Dosing
Also known as: Upadacitinib
Percentage of Participants Who Achieve Endoscopic Remission at Week 12/16
Endoscopic remission was determined using Simplified Endoscopic Score for Crohn's Disease (SES-CD). SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable.
Time frame: Up to Week 16. (At Baseline, participants were allocated by randomization 1:1 to have their end of induction colonoscopy done at either Week 12 or Week 16; this endpoint combines the two time points.)
Percentage of Participants Who Achieve Clinical Remission at Week 16
Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
Time frame: Week 16
Percentage of Participants Who Achieve Crohn's Disease Activity Index (CDAI) < 150 at Week 16
CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A score below 150 indicates remission.
Time frame: Week 16
Percentage of Participants With a Decrease in CDAI ≥ 70 Points From Baseline at Week 16
CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A 70-point decrease in the CDAI index refers to improvement in the disease activity from Baseline.
Time frame: Week 16
Percentage of Participants Who Achieve Clinical Remission at Week 12
Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
Time frame: Week 12
Percentage of Participants Who Achieve Remission at Week 16
Remission is defined as endoscopic remission at Week 12/16 AND clinical remission at Week 16. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.
Time frame: Week 16
Percentage of Participants Who Achieve Response at Week 16
Response is defined as endoscopic response at Week 12/16 AND clinical response at Week 16. Endoscopic response: SES-CD at least 25% reduction from Baseline. Clinical response: average daily stool frequency at least 30% reduction from Baseline and average daily abdominal pain not worse than Baseline OR average daily abdominal pain at least 30% reduction from Baseline and average daily stool frequency not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.
Time frame: Week 16
Percentage of Participants With Endoscopic Response at Week 12/16
Endoscopic response: SES-CD at least 25% reduction from Baseline. Details of the SES-CD scale are provided in the description of the first primary endpoint.
Time frame: Up to Week 16 (At Baseline, participants were allocated by randomization 1:1 to have their end of induction colonoscopy done at either Week 12 or Week 16; this endpoint combines the two time points.)
Percentage of Participants Who Achieve Clinical Response at Week 16
Clinical response: average daily stool frequency at least 30% reduction from Baseline and average daily abdominal pain not worse than Baseline OR average daily abdominal pain at least 30% reduction from Baseline and average daily stool frequency not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
Time frame: Week 16
Percentage of Participants With an Average Daily Stool Frequency ≥ 2.5 AND Average Daily Abdominal Pain ≥ 2.0 at Baseline Who Achieve Clinical Remission at Week 16
Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
Time frame: Week 16
Percentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve CDAI < 150 at Week 16
CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A score below 150 indicates remission.
Time frame: Week 16
Percentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve Remission at Week 12/16 and Clinical Remission at Week 16
Remission is defined as endoscopic remission at Week 12/16 AND clinical remission at Week 16. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.
Time frame: Up to Week 16. (At Baseline, subjects were allocated by randomization 1:1 to have their end of induction colonoscopy done at either Week 12 or Week 16; this endpoint combines the two time points.)
Percentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve Clinical Remission at Week 16
Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
Time frame: Week 16
Percentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve Endoscopic Remission at Week 12/16
Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Details of the SES-CD scale are provided in the description of the first primary endpoint.
Time frame: Up to Week 16. (At Baseline, participants were allocated by randomization 1:1 to have their end of induction colonoscopy done at either Week 12 or Week 16; this endpoint combines the two time points.)
Change From Baseline in Fecal Calprotectin Level Over Time During the Induction Phase
Time frame: Baseline, Week 4, Week 16
Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) at Week 16
Time frame: Baseline, Week 16
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Over Time During the Induction Phase
The IBDQ is a disease-specific instrument composed of 32 Likert-scaled items. The total score ranges from 32 to 224 using the 7-point response options, with higher scores indicating better health-related quality of life.
Time frame: Baseline, Week 8, Week 16
Percentage of Participants With Isolated Ileal Crohn's Disease at Baseline Who Achieve Remission at Week 16
Remission is defined as endoscopic remission AND clinical remission. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.
Time frame: Week 16
Percentage of Participants With a Decrease in CDAI ≥ 100 Points From Baseline at Week 16
CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A score below 150 indicates remission and a score above 450 indicates very severe disease.
Time frame: Week 16
Percentage of Participants Who Achieve > 50% Reduction From Baseline in SES-CD or Endoscopic Remission at Week 12/16
Endoscopic remission: SES-CD ≤ 4 and at least two point reduction versus Baseline and no subscore \> 1 in any individual variable. Details of the SES-CD scale are provided in the description of the first primary endpoint.
Time frame: Up to Week 16. (At Baseline, participants were allocated by randomization 1:1 to have their end of induction colonoscopy done at either Week 12 or Week 16; this endpoint combines the two time points.)
Percentage of Participants Who Achieve Modified Clinical Remission at Week 16 Among Participants With an Average Daily Stool Frequency ≥ 4.0 or Average Daily Abdominal Pain ≥ 2.0 at Baseline
Modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than Baseline and average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
Time frame: Week 16
Change From Baseline in Abdominal Pain Rating Scale at Week 12
Abdominal pain was assessed on an abdominal pain rating scale, where subjects rated their average abdominal pain over the last 24 hours on a scale of 0 (none) to 10 (worst pain imaginable).
Time frame: Baseline, Week 12
Change From Baseline in Abdominal Pain Rating Scale at Week 16
Abdominal pain was assessed on an abdominal pain rating scale, where subjects rated their average abdominal pain over the last 24 hours on a scale of 0 (none) to 10 (worst pain imaginable).
Time frame: Baseline, Week 16
Percentage of Participants Who Achieve Remission at Week 52
Remission at Week 52 was defined as both endoscopic remission at Week 52 and clinical remission at Week 52. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). See SES-CD description details in the first primary endpoint description of this record. See definitions of responder and clinical responder in Outcome Measure 7 of this record.
Time frame: Week 52
Percentage of Participants Who Achieve Endoscopic Remission at Week 52
Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Details of the SES-CD scale are provided in the description of the first primary endpoint.
Time frame: Week 52
Percentage of Participants Who Achieve Both Endoscopic Remission and Modified Clinical Remission at Week 52 Among Subjects With Daily Stool Frequency ≥ 4.0 or Daily Abdominal Pain ≥ 2.0 at Induction Baseline
Endoscopic remission was defined as SES-CD \<= 4 and at least 2 points reduction versus induction baseline and no subscore \> 1 in any individual variable. Modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than induction baseline AND average daily abdominal pain \<= 1.0 and not worse than induction baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). See SES-CD description details in the first primary endpoint description of this record.
Time frame: Week 52
Percentage of Participants Who Achieve Clinical Remission Over Time During Extension Phase in Participants Receiving Upadacitinib in Induction
Clinical remission was defined as average daily stool frequency \<= 1.5 and not worse than Induction Baseline and average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
Time frame: Week 20, Week 28, Week 36, Week 44, Week 52
Percentage of Participants Who Maintain Clinical Remission Over Time Among Participants in Clinical Remission at Week 16 in Participants Receiving Upadacitinib in Induction
Clinical remission was defined as average daily stool frequency \<= 1.5 and not worse than Induction Baseline and average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
Time frame: Week 20, Week 28, Week 36, Week 44, Week 52
Percentage of Participants Who Achieve Modified Clinical Remission Over Time During Extension Phase Among Participants With Daily Stool Frequency ≥ 4.0 or Daily Abdominal Pain ≥ 2.0 at Induction Baseline
Modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than Induction Baseline and average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
Time frame: Week 20, Week 28, Week 36, Week 44, Week 52
Percentage of Participants Who Achieve Modified Clinical Remission Over Time During Extension Phase Among Participants In Modified Clinical Remission At Week 16 and Daily Stool Frequency ≥ 4.0 or Daily Abdominal Pain ≥ 2.0 at Induction Baseline
Modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than Induction Baseline and average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
Time frame: Week 20, Week 28, Week 36, Week 44, Week 52
Percentage of Participants Who Achieve Response at Week 52
Response at Week 52 was defined as both endoscopic response at Week 52 and clinical response at Week 52. Endoscopic response: SES-CD at least 25% reduction from Baseline. Clinical response: average daily stool frequency at least 30% reduction from Induction Baseline and average daily abdominal pain not worse than Induction Baseline OR average daily abdominal pain at least 30% reduction from Induction Baseline and average daily stool frequency not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.
Time frame: Week 52
Percentage of Participants With SES-CD ≤ 2 at Week 52
SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.
Time frame: Week 52
Percentage of Participants With SES-CD = 0 at Week 52
SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.
Time frame: Week 52
Percentage of Participants Who Achieve Endoscopic Response at Week 52
Endoscopic response was defined as SES-CD at least 25% reduction from Induction Baseline. SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.
Time frame: Week 52
Percentage of Participants Who Achieve Enhanced Endoscopic Response at Week 52
Enhanced endoscopic response was defined as SES-CD reduction from Induction Baseline \> 50% (or for an Induction Baseline SES-CD of 4, at least a 2 point reduction from Induction Baseline). SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.
Time frame: Week 52
Percentage of Participants Who Achieve Endoscopic Improvement at Week 52
Endoscopic Improvement: SES-CD reduction from Induction Baseline \> 50% or endoscopic remission. Endoscopic remission was defined as SES-CD \<= 4 and at least 2 points reduction versus Induction Baseline and no subscore \> 1 in any individual variable. SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.
Time frame: Week 52
Percentage of Participants Who Achieve Endoscopic Healing at Week 52
Endoscopic healing was defined as SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore \>= 1 at Induction Baseline. SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.
Time frame: Week 52
Percentage of Participants Who Achieve Clinical Response Over Time During Extension Phase
Clinical response was defined as average daily stool frequency at least 30% reduction from Induction Baseline and average daily abdominal pain not worse than Induction Baseline OR average daily abdominal pain at least 30% reduction from Induction Baseline and average daily stool frequency not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
Time frame: Week 20, Week 28, Week 36, Week 44, Week 52
Percentage of Participants Who Achieve Enhanced Clinical Response Over Time During Extension Phase
Enhanced clinical response was defined as average daily stool frequency at least 60% reduction from Induction Baseline and average daily abdominal pain not worse than Induction Baseline OR average daily abdominal pain at least 35% reduction from Induction Baseline and average daily stool frequency not worse than Induction Baseline or modified clinical remission (average daily stool frequency ≤ 2.8 and not worse than Induction baseline AND average daily abdominal pain ≤ 1.0 and not worse than Induction baseline). The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
Time frame: Week 20, Week 28, Week 36, Week 44, Week 52
Percentage of Participants Who Achieve Enhanced Clinical Response Over Time During Extension Phase Among Participants In Enhanced Clinical Response At Week 16
Enhanced clinical response was defined as average daily stool frequency at least 60% reduction from Induction Baseline and average daily abdominal pain not worse than Induction Baseline or average daily abdominal pain at least 35% reduction from Induction Baseline and average daily stool frequency not worse than Induction Baseline or modified clinical remission (average daily stool frequency ≤ 2.8 and not worse than Induction baseline AND average daily abdominal pain ≤ 1.0 and not worse than Induction baseline). The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
Time frame: Week 20, Week 28, Week 36, Week 44, Week 52
Percentage of Participants Who Achieve Clinical Remission Over Time During Extension Phase Among Participants With an Average Daily Stool Frequency ≥ 2.5 and Average Daily Abdominal Pain ≥ 2.0 at Induction Baseline
Clinical remission was defined as average daily stool frequency \<= 1.5 and not worse than Induction Baseline AND average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
Time frame: Week 20, Week 28, Week 36, Week 44, Week 52
Percentage of Participants Taking Corticosteroids at Induction Baseline Who Discontinued Corticosteroid Use and Achieve CDAI < 150 Over Time
CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A score below 150 indicates remission.
Time frame: Week 20, Week 28, Week 36, Week 44, Week 52
Percentage of Participants Taking Corticosteroids at Induction Baseline Who Discontinued Corticosteroid Use and Achieve Remission At Week 52
Steroid-free remission at Week 52 was defined as both endoscopic remission at Week 52 and clinical remission at Week 52. Endoscopic remission: SES-CD ≤ 4 and at least 2 point reduction versus Induction Baseline and no subscore \> 1 in any individual variable. Clinical remission: Average daily stool frequency ≤ 1.5 and not worse than baseline AND average daily abdominal pain ≤ 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). See SES-CD description details in the first primary endpoint description of this record.
Time frame: Baseline, Week 52
Percentage of Participants Taking Corticosteroids at Induction Baseline Who Discontinued Corticosteroid Use and Achieve Clinical Remission Over Time
Steroid-free clinical remission was defined as average daily stool frequency \<= 1.5 and not worse than Induction Baseline AND average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
Time frame: Week 20, Week 28, Week 36, Week 44, Week 52
Percentage of Participants Taking Corticosteroids at Induction Baseline and With Daily Stool Frequency ≥ 4.0 or Daily Abdominal Pain ≥ 2.0 at Induction Baseline Who Discontinued Corticosteroid Use and Achieve Modified Clinical Remission Over Time
Steroid-free modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than Induction Baseline AND average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
Time frame: Week 20, Week 28, Week 36, Week 44, Week 52
Percentage of Participants Taking Corticosteroids at Induction Baseline Who Discontinued Corticosteroid Use and Achieve Endoscopic Remission at Week 52
Steroid-free endoscopic remission was defined as SES-CD \<= 4 and at least 2 points reduction versus Induction Baseline and no subscore \> 1 in any individual variable. Details of the SES-CD scale are provided in the description of the first primary endpoint.
Time frame: Baseline, Week 52
Percentage Of Participants Who Achieve CDAI < 150 Over Time During Extension Phase
CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A score below 150 indicates remission.
Time frame: Week 20, Week 28, Week 36, Week 44, Week 52
Percentage of Participants With Decrease in CDAI ≥ 70 Points From Induction Baseline Over Time During Extension Phase
CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A 70-point decrease in the CDAI index refers to improvement in the disease activity from Baseline.
Time frame: Week 20, Week 28, Week 36, Week 44, Week 52
Change From Induction Baseline in Fecal Calprotectin Level Over Time During Extension Phase
Time frame: Baseline, Week 28, Week 52
Change From Induction Baseline in Hs-CRP Over Time During Extension Phase
Time frame: Baseline, Week 20, Week 28, Week 36, Week 44, Week 52
Change From Induction Baseline in IBDQ at Week 52
The IBDQ is a disease-specific instrument composed of 32 Likert-scaled items. The total score ranges from 32 to 224 using the 7-point response options, with higher scores indicating better health-related quality of life. The IBDQ scale contains 4 component subscales: bowel symptoms, systemic symptoms, emotional function, and social function. Each subscale can be computed with total scores ranging from 10 to 70, 5 to 35, 12 to 84, and 5 to 35, respectively.
Time frame: Baseline, Week 52
Change From Induction Baseline in European Quality of Life (EuroQol) 5 Dimensions Questionnaire (EQ-5D) Index Score at Week 52
The EQ-5D is a standardized instrument for use as a measure of health-related quality of life. The EQ-5D Index Score has five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Health states are converted into a weighted health state index. These weights lie on a scale on which full health has a value of 1 and dead has a value of 0. A positive change represents an improvement in health-related quality of life.
Time frame: Baseline, Week 52
Change From Induction Baseline in EQ-5D VAS at Week 52
The EQ-5D is a standardized instrument for use as a measure of health-related quality of life. The EQ-5D VAS is a 20-cm scale with endpoints labeled "best imaginable health" and "worst imaginable health" anchored at 100 and 0, respectively. A positive change represents an improvement in health-related quality of life.
Time frame: Baseline, Week 52
Cross Tabulation of Induction Baseline and Week 52 in Total Number of Extra-Intestinal Manifestations (EIMs) of Crohn's Disease
Presented as percentage of participants with given number of EIMs at Baseline (BL) and Week (Wk) 52. EIMs of Crohn's disease included anemia, autoimmune hepatitis, axial arthropathy, bronchiectasis, chronic obstructive pulmonary disease, episcleritis, erythema nodosum, iritis, nephrolithiasis, oral aphthous ulcers, peripheral arthropathy, primary sclerosing cholangitis, pyoderma gangrenosum, Sweet's syndrome, uveitis, and venous thromboembolism.
Time frame: Baseline, Week 52
Percentage of Participants Who Achieve Remission at Week 52 Among Participants With Isolated Ileal Crohn's Disease at Baseline
Remission at Week 52 is defined as endoscopic remission at Week 52 AND clinical remission at Week 52. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.
Time frame: Baseline, Week 52
Percentage of Participants Who Achieve Modified Clinical Remission at Week 52 Among Participants With Isolated Ileal Crohn's Disease at Baseline And Daily Stool Frequency ≥ 4.0 or Daily Abdominal Pain ≥ 2.0 at Induction Baseline
Modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than induction baseline AND average daily abdominal pain \<= 1.0 and not worse than induction baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
Time frame: Week 52
| Milestone | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD | Double Blind Extension Phase: Upadacitinib 3 mg BID | Double Blind Extension Phase: Upadacitinib 6 mg BID | Double Blind Extension Phase: Upadacitinib 12 mg BID | Double Blind Extension Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 37 | 39 | 37 | 36 | 36 | 35 | 0 | 0 | 0 | 0 |
| Completed | 27 | 34 | 33 | 27 | 29 | 30 | 0 | 0 | 0 | 0 |
| Not completed | 10 | 5 | 4 | 9 | 7 | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Requires alternative therapy | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 4 | 0 | 7 | 1 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 3 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Subject non-compliance | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD | Double Blind Extension Phase: Upadacitinib 3 mg BID | Double Blind Extension Phase: Upadacitinib 6 mg BID | Double Blind Extension Phase: Upadacitinib 12 mg BID | Double Blind Extension Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 61 | 23 | 59 | 37 |
| Switched to ol 12 mg bid | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 5 | 17 | 17 |
| Further dose escalated to ol 24 mg bid | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 2 | 10 | 10 |
| Dose de-escalated to ol 12 mg bid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 43 | 21 | 43 | 22 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 18 | 2 | 16 | 15 |
| Withdrew: Requires alternative therapy | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 4 | 4 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 2 | 8 | 10 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 |
| Withdrew: Subject noncompliance | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 0 |
Endoscopic remission was determined using Simplified Endoscopic Score for Crohn's Disease (SES-CD). SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable.
| percentage of participants | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieve Endoscopic Remission at Week 12/16 | 0 | 10.3 | 8.1 | 8.3 | 22.2 | 14.3 |
Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
| percentage of participants | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieve Clinical Remission at Week 16 | 10.8 | 12.8 | 27.0 | 11.1 | 22.2 | 14.3 |
CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A score below 150 indicates remission.
| percentage of participants | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieve Crohn's Disease Activity Index (CDAI) < 150 at Week 16 | 16.2 | 20.5 | 29.7 | 38.9 | 30.6 | 20.0 |
CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A 70-point decrease in the CDAI index refers to improvement in the disease activity from Baseline.
| percentage of participants | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants With a Decrease in CDAI ≥ 70 Points From Baseline at Week 16 | 35.1 | 46.2 | 54.1 | 44.4 | 61.1 | 48.6 |
Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
| percentage of participants | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieve Clinical Remission at Week 12 | 10.8 | 10.3 | 29.7 | 13.9 | 25.0 | 8.6 |
Remission is defined as endoscopic remission at Week 12/16 AND clinical remission at Week 16. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.
| percentage of participants | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieve Remission at Week 16 | 0.0 | 2.6 | 5.4 | 2.8 | 8.3 | 5.7 |
Response is defined as endoscopic response at Week 12/16 AND clinical response at Week 16. Endoscopic response: SES-CD at least 25% reduction from Baseline. Clinical response: average daily stool frequency at least 30% reduction from Baseline and average daily abdominal pain not worse than Baseline OR average daily abdominal pain at least 30% reduction from Baseline and average daily stool frequency not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.
| percentage of participants | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieve Response at Week 16 | 2.7 | 15.4 | 32.4 | 27.8 | 38.9 | 34.3 |
Endoscopic response: SES-CD at least 25% reduction from Baseline. Details of the SES-CD scale are provided in the description of the first primary endpoint.
| percentage of participants | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants With Endoscopic Response at Week 12/16 | 13.5 | 23.1 | 43.2 | 36.1 | 50.0 | 48.6 |
Clinical response: average daily stool frequency at least 30% reduction from Baseline and average daily abdominal pain not worse than Baseline OR average daily abdominal pain at least 30% reduction from Baseline and average daily stool frequency not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
| percentage of participants | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieve Clinical Response at Week 16 | 32.4 | 43.6 | 56.8 | 47.2 | 61.1 | 48.6 |
Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
| percentage of participants | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants With an Average Daily Stool Frequency ≥ 2.5 AND Average Daily Abdominal Pain ≥ 2.0 at Baseline Who Achieve Clinical Remission at Week 16 | 7.1 | 17.6 | 18.8 | 16.7 | 25.0 | 11.1 |
CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A score below 150 indicates remission.
| percentage of participants | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve CDAI < 150 at Week 16 | 0.0 | 19.0 | 22.2 | 41.2 | 33.3 | 10.0 |
Remission is defined as endoscopic remission at Week 12/16 AND clinical remission at Week 16. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.
| percentage of participants | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve Remission at Week 12/16 and Clinical Remission at Week 16 | 0.0 | 0.0 | 5.6 | 5.9 | 13.3 | 0.0 |
Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
| percentage of participants | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve Clinical Remission at Week 16 | 0.0 | 14.3 | 22.2 | 11.8 | 33.3 | 10.0 |
Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Details of the SES-CD scale are provided in the description of the first primary endpoint.
| percentage of participants | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve Endoscopic Remission at Week 12/16 | 0.0 | 0.0 | 11.1 | 5.9 | 20.0 | 10.0 |
| μg/g | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Week 4 | 83.7 ± 1024.11 | -310.3 ± 2415.43 | -436.9 ± 1505.75 | -915.7 ± 1600.31 | -876.2 ± 2240.93 | -255.8 ± 2407.47 |
| Week 16 | -128.9 ± 373.53 | -534.5 ± 3279.19 | -429.4 ± 2505.21 | -475.1 ± 2668.93 | -828.7 ± 986.09 | -698.4 ± 2228.85 |
| mg/L | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) at Week 16 | -0.1 ± 11.96 | -3.0 ± 19.60 | -3.9 ± 19.47 | -6.1 ± 27.02 | -14.8 ± 26.38 | -2.7 ± 13.74 |
The IBDQ is a disease-specific instrument composed of 32 Likert-scaled items. The total score ranges from 32 to 224 using the 7-point response options, with higher scores indicating better health-related quality of life.
| units on a scale | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Week 8 | 16.6 ± 25.38 | 18.9 ± 40.35 | 34.6 ± 36.22 | 24.9 ± 30.95 | 39.7 ± 40.76 | 23.3 ± 30.34 |
| Week 16 | 14.5 ± 29.15 | 24.6 ± 42.98 | 41.8 ± 47.02 | 32.1 ± 38.57 | 44.4 ± 40.05 | 22.5 ± 27.82 |
Remission is defined as endoscopic remission AND clinical remission. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.
| percentage of participants | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants With Isolated Ileal Crohn's Disease at Baseline Who Achieve Remission at Week 16 | 0.0 | 20.0 | 16.7 | 20.0 | 0.0 | 20.0 |
CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A score below 150 indicates remission and a score above 450 indicates very severe disease.
| percentage of participants | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants With a Decrease in CDAI ≥ 100 Points From Baseline at Week 16 | 27.0 | 33.3 | 40.5 | 44.4 | 55.6 | 31.4 |
Endoscopic remission: SES-CD ≤ 4 and at least two point reduction versus Baseline and no subscore \> 1 in any individual variable. Details of the SES-CD scale are provided in the description of the first primary endpoint.
| percentage of participants | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieve > 50% Reduction From Baseline in SES-CD or Endoscopic Remission at Week 12/16 | 2.7 | 12.8 | 18.9 | 25.0 | 36.1 | 25.7 |
Modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than Baseline and average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
| percentage of participants | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieve Modified Clinical Remission at Week 16 Among Participants With an Average Daily Stool Frequency ≥ 4.0 or Average Daily Abdominal Pain ≥ 2.0 at Baseline | 12.1 | 15.8 | 30.3 | 26.5 | 36.7 | 18.8 |
Abdominal pain was assessed on an abdominal pain rating scale, where subjects rated their average abdominal pain over the last 24 hours on a scale of 0 (none) to 10 (worst pain imaginable).
| units on a scale | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Change From Baseline in Abdominal Pain Rating Scale at Week 12 | -1.1 ± 1.84 | -1.0 ± 2.61 | -2.6 ± 2.53 | -2.4 ± 3.17 | -2.7 ± 2.52 | -1.0 ± 1.99 |
Abdominal pain was assessed on an abdominal pain rating scale, where subjects rated their average abdominal pain over the last 24 hours on a scale of 0 (none) to 10 (worst pain imaginable).
| units on a scale | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Change From Baseline in Abdominal Pain Rating Scale at Week 16 | -0.9 ± 2.27 | -1.7 ± 3.02 | -2.8 ± 2.77 | -1.7 ± 2.86 | -2.3 ± 2.42 | -1.4 ± 2.15 |
Remission at Week 52 was defined as both endoscopic remission at Week 52 and clinical remission at Week 52. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). See SES-CD description details in the first primary endpoint description of this record. See definitions of responder and clinical responder in Outcome Measure 7 of this record.
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/Placebo in Induction | Upadacitinib 6 mg BID in Extension/Placebo in Induction | Upadacitinib 12 mg BID in Extension/Placebo in Induction | Upadacitinib 24 mg QD in Extension/Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders | 20.0 | 12.5 | 25.0 | 0.0 | 0.0 | — | — | — |
| Non-Responders | 0.0 | 0.0 | 2.9 | 13.0 | 0.0 | 0.0 | 0.0 | 25.0 |
| Clinical Responders | 12.5 | 7.1 | 13.8 | 15.8 | 0.0 | 0.0 | 0.0 | 100 |
| Clinical Non-Responders | 0.0 | 0.0 | 4.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Details of the SES-CD scale are provided in the description of the first primary endpoint.
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders | 25.0 | 25.0 | 37.5 | 10.0 | 0 | — | — | — |
| Non-Responders | 3.1 | 10.0 | 8.8 | 17.4 | 0 | 0 | 0 | 25.0 |
| Clinical Responders | 15.6 | 21.4 | 24.1 | 26.3 | 0 | 0 | 0 | 100 |
| Clinical Non-Responders | 5.0 | 0 | 9.5 | 0 | 0 | 0 | 0 | 0 |
Endoscopic remission was defined as SES-CD \<= 4 and at least 2 points reduction versus induction baseline and no subscore \> 1 in any individual variable. Modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than induction baseline AND average daily abdominal pain \<= 1.0 and not worse than induction baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). See SES-CD description details in the first primary endpoint description of this record.
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders | 29.4 | 12.5 | 33.3 | 10.0 | 0 | — | — | — |
| Non-responders | 0 | 0 | 6.1 | 15.0 | 0 | 0 | 0 | 25.0 |
| Clinical responders | 17.9 | 7.1 | 22.2 | 22.2 | 0 | 0 | 0 | 100 |
| Clinical non-responders | 0 | 0 | 4.8 | 0 | 0 | 0 | 0 | 0 |
Clinical remission was defined as average daily stool frequency \<= 1.5 and not worse than Induction Baseline and average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction |
|---|---|---|---|---|
| Responders, Week 20 | 45.0 | 37.5 | 50.0 | 40.0 |
| Responders, Week 28 | 45.0 | 37.5 | 56.3 | 50.0 |
| Responders, Week 36 | 40.0 | 37.5 | 62.5 | 30.0 |
| Responders, Week 44 | 40.0 | 12.5 | 68.8 | 40.0 |
| Responders, Week 52 | 30.0 | 37.5 | 62.5 | 30.0 |
| Non-responders, Week 20 | 12.5 | 40.0 | 8.8 | 8.7 |
| Non-responders, Week 28 | 12.5 | 40.0 | 8.8 | 13.0 |
| Non-responders, Week 36 | 9.4 | 10.0 | 2.9 | 13.0 |
| Non-responders, Week 44 | 12.5 | 20.0 | 5.9 | 8.7 |
| Non-responders, Week 52 | 9.4 | 10.0 | 8.8 | 13.0 |
| Clinical responders, Week 20 | 40.6 | 50.0 | 37.9 | 31.6 |
| Clinical responders, Week 28 | 37.5 | 50.0 | 41.4 | 42.1 |
| Clinical responders, Week 36 | 34.4 | 28.6 | 37.9 | 31.9 |
| Clinical responders, Week 44 | 34.4 | 21.4 | 44.8 | 31.6 |
| Clinical responders, Week 52 | 25.0 | 28.6 | 41.4 | 31.6 |
| Clinical non-responders, Week 20 | 0 | 0 | 0 | 0 |
| Clinical non-responders, Week 28 | 5.0 | 0 | 0 | 0 |
| Clinical non-responders, Week 36 | 0 | 0 | 0 | 0 |
| Clinical non-responders, Week 44 | 5.0 | 0 | 0 | 0 |
| Clinical non-responders, Week 52 | 5.0 | 0 | 4.8 | 0 |
Clinical remission was defined as average daily stool frequency \<= 1.5 and not worse than Induction Baseline and average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction |
|---|---|---|---|---|
| Responders, Week 20 | 80.0 | 66.7 | 71.4 | 100 |
| Responders, Week 28 | 90.0 | 66.7 | 57.1 | 100 |
| Responders, Week 36 | 80.0 | 100 | 71.4 | 66.7 |
| Responders, Week 44 | 80.0 | 33.3 | 71.4 | 66.7 |
| Responders, Week 52 | 60.0 | 66.7 | 71.4 | 66.7 |
| Non-responders, Week 20 | 66.7 | 100 | 50.0 | 100 |
| Non-responders, Week 28 | 66.7 | 100 | 50.0 | 100 |
| Non-responders, Week 36 | 66.7 | 33.3 | 50.0 | 100 |
| Non-responders, Week 44 | 66.7 | 66.7 | 50.0 | 100 |
| Non-responders, Week 52 | 33.3 | 33.3 | 0 | 100 |
| Clinical responders, Week 20 | 76.9 | 83.3 | 66.7 | 100 |
| Clinical responders, Week 28 | 84.6 | 83.3 | 55.6 | 100 |
| Clinical responders, Week 36 | 76.9 | 66.7 | 66.7 | 75.0 |
| Clinical responders, Week 44 | 76.9 | 50.0 | 66.7 | 75.0 |
| Clinical responders, Week 52 | 53.8 | 50.0 | 55.6 | 75.0 |
Modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than Induction Baseline and average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders, Week 20 | 47.1 | 62.5 | 66.7 | 60.0 | 0 | — | — | — |
| Responders, Week 28 | 70.6 | 50.0 | 66.7 | 60.0 | 0 | — | — | — |
| Responders, Week 36 | 58.8 | 87.5 | 73.3 | 30.0 | 0 | — | — | — |
| Responders, Week 44 | 47.1 | 37.5 | 73.3 | 40.0 | 0 | — | — | — |
| Responders, Week 52 | 41.2 | 62.5 | 73.3 | 40.0 | 0 | — | — | — |
| Non-responders, Week 20 | 17.9 | 44.4 | 12.1 | 10.0 | 42.9 | 20.0 | 25.0 | 25.0 |
| Non-responders, Week 28 | 21.4 | 44.4 | 9.1 | 15.0 | 42.9 | 20.0 | 25.0 | 50.0 |
| Non-responders, Week 36 | 14.3 | 11.1 | 6.1 | 15.0 | 57.1 | 20.0 | 25.0 | 25.0 |
| Non-responders, Week 44 | 14.3 | 22.2 | 6.1 | 10.0 | 42.9 | 20.0 | 37.5 | 25.0 |
| Non-responders, Week 52 | 7.1 | 11.1 | 12.1 | 15.0 | 28.6 | 0 | 37.5 | 50.0 |
| Clinical responders, Week 20 | 42.9 | 64.3 | 51.9 | 44.4 | 60.0 | 100 | 33.3 | 100 |
| Clinical responders, Week 28 | 57.1 | 57.1 | 48.1 | 50.0 | 60.0 | 100 | 33.3 | 100 |
| Clinical responders, Week 36 | 46.4 | 57.1 | 48.1 | 33.3 | 80.0 | 100 | 33.3 | 100 |
| Clinical responders, Week 44 | 39.3 | 35.7 | 48.1 | 33.3 | 60.0 | 100 | 33.3 | 100 |
| Clinical responders, Week 52 | 28.6 | 42.9 | 51.9 | 38.9 | 40.0 | 0 | 33.3 | 100 |
| Clinical non-responders, Week 20 | 5.9 | 0 | 0 | 0 | 0 | 0 | 20.0 | 0 |
| Clinical non-responders, Week 28 | 11.8 | 0 | 0 | 0 | 0 | 0 | 20.0 | 33.3 |
| Clinical non-responders, Week 36 | 5.9 | 0 | 0 | 0 | 0 | 0 | 20.0 | 0 |
| Clinical non-responders, Week 44 | 5.9 | 0 | 0 | 0 | 0 | 0 | 40.0 | 0 |
| Clinical non-responders, Week 52 | 5.9 | 0 | 4.8 | 0 | 0 | 0 | 40.0 | 33.3 |
Modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than Induction Baseline and average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders, Week 20 | 66.7 | 60.0 | 90.0 | 100 | — | — | — | — |
| Responders, Week 28 | 91.7 | 60.0 | 90.0 | 100 | — | — | — | — |
| Responders, Week 36 | 66.7 | 100 | 90.0 | 75.0 | — | — | — | — |
| Responders, Week 44 | 66.7 | 40.0 | 90.0 | 75.0 | — | — | — | — |
| Responders, Week 52 | 58.3 | 80.0 | 90.0 | 75.0 | — | — | — | — |
| Non-responders, Week 20 | 66.7 | 80.0 | 50.0 | 100 | 100 | — | 100 | 100 |
| Non-responders, Week 28 | 100 | 60.0 | 50.0 | 100 | 100 | — | 100 | 100 |
| Non-responders, Week 36 | 66.7 | 20.0 | 50.0 | 100 | 100 | — | 100 | 100 |
| Non-responders, Week 44 | 66.7 | 40.0 | 50.0 | 100 | 50.0 | — | 100 | 100 |
| Non-responders, Week 52 | 33.3 | 20.0 | 50.0 | 100 | 50.0 | — | 100 | 100 |
| Clinical responders, Week 20 | 66.7 | 70.0 | 83.3 | 100 | 100 | — | 100 | 100 |
| Clinical responders, Week 28 | 93.3 | 60.0 | 83.3 | 100 | 100 | — | 100 | 100 |
| Clinical responders, Week 36 | 66.7 | 60.0 | 83.3 | 80.0 | 100 | — | 100 | 100 |
| Clinical responders, Week 44 | 66.7 | 40.0 | 83.3 | 80.0 | 50.0 | — | 100 | 100 |
| Clinical responders, Week 52 | 53.3 | 50.0 | 83.3 | 80.0 | 50.0 | — | 100 | 100 |
Response at Week 52 was defined as both endoscopic response at Week 52 and clinical response at Week 52. Endoscopic response: SES-CD at least 25% reduction from Baseline. Clinical response: average daily stool frequency at least 30% reduction from Induction Baseline and average daily abdominal pain not worse than Induction Baseline OR average daily abdominal pain at least 30% reduction from Induction Baseline and average daily stool frequency not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders | 50.0 | 62.5 | 68.8 | 40.0 | 100 | — | — | — |
| Non-responders | 6.3 | 10.0 | 14.7 | 13.0 | 0 | 20.0 | 22.2 | 25.0 |
| Clinical responders | 34.4 | 42.9 | 51.7 | 36.8 | 16.7 | 0 | 0 | 100 |
| Clinical non-responders | 5.0 | 0 | 4.8 | 0 | 0 | 25.0 | 40.0 | 0 |
SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders | 10.0 | 12.5 | 31.3 | 0 | 0 | — | — | — |
| Non-responders | 6.3 | 0 | 8.8 | 8.7 | 0 | 0 | 0 | 25.0 |
| Clinical responders | 6.3 | 7.1 | 20.7 | 10.5 | 0 | 0 | 0 | 100 |
| Clinical non-responders | 10.0 | 0 | 9.5 | 0 | 0 | 0 | 0 | 0 |
SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders | 10.0 | 12.5 | 31.3 | 0 | 0 | — | — | — |
| Non-responders | 3.1 | 0 | 8.8 | 4.3 | 0 | 0 | 0 | 0 |
| Clinical responders | 6.3 | 7.1 | 20.7 | 5.3 | 0 | 0 | 0 | 0 |
| Clinical non-responders | 5.0 | 0 | 9.5 | 0 | 0 | 0 | 0 | 0 |
Endoscopic response was defined as SES-CD at least 25% reduction from Induction Baseline. SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders | 60.0 | 75.0 | 75.0 | 40.0 | 100 | — | — | — |
| Non-responders | 15.6 | 20.0 | 20.6 | 17.4 | 0 | 20.0 | 22.2 | 25.0 |
| Clinical responders | 40.6 | 57.1 | 55.2 | 42.1 | 16.7 | 0 | 0 | 100 |
| Clinical non-responders | 20.0 | 0 | 14.3 | 0 | 0 | 25.0 | 40.0 | 0 |
Enhanced endoscopic response was defined as SES-CD reduction from Induction Baseline \> 50% (or for an Induction Baseline SES-CD of 4, at least a 2 point reduction from Induction Baseline). SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders | 40.0 | 50.0 | 68.8 | 30.0 | 100 | — | — | — |
| Non-responders | 12.5 | 0 | 11.8 | 17.4 | 0 | 20.0 | 11.1 | 25.0 |
| Clinical responders | 28.1 | 28.6 | 44.8 | 36.8 | 16.7 | 0 | 0 | 100 |
| Clinical non-responders | 15.0 | 0 | 9.5 | 0 | 0 | 25.0 | 20.0 | 0 |
Endoscopic Improvement: SES-CD reduction from Induction Baseline \> 50% or endoscopic remission. Endoscopic remission was defined as SES-CD \<= 4 and at least 2 points reduction versus Induction Baseline and no subscore \> 1 in any individual variable. SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders | 50.0 | 50.0 | 68.8 | 30.0 | 100 | — | — | — |
| Non-responders | 12.5 | 10.0 | 11.8 | 17.4 | 0 | 20.0 | 11.1 | 25.0 |
| Clinical responders | 34.4 | 35.7 | 44.8 | 36.8 | 16.7 | 0 | 0 | 100 |
| Clinical non-responders | 15.0 | 0 | 9.5 | 0 | 0 | 25.0 | 20.0 | 0 |
Endoscopic healing was defined as SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore \>= 1 at Induction Baseline. SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders | 15.0 | 25.0 | 50.0 | 0 | 0 | — | — | — |
| Non-responders | 9.4 | 10.0 | 8.8 | 8.7 | 0 | 20.0 | 0 | 0 |
| Clinical responders | 9.4 | 21.4 | 31.0 | 10.5 | 0 | 0 | 0 | 0 |
| Clinical non-responders | 15.0 | 0 | 9.5 | 0 | 0 | 25.0 | 0 | 0 |
Clinical response was defined as average daily stool frequency at least 30% reduction from Induction Baseline and average daily abdominal pain not worse than Induction Baseline OR average daily abdominal pain at least 30% reduction from Induction Baseline and average daily stool frequency not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders, Week 20 | 85.0 | 100 | 100 | 80.0 | 100 | — | — | — |
| Responders, Week 28 | 85.0 | 75.0 | 81.3 | 60.0 | 0 | — | — | — |
| Responders, Week 36 | 75.0 | 100 | 75.0 | 50.0 | 100 | — | — | — |
| Responders, Week 44 | 50.0 | 87.5 | 81.3 | 40.0 | 0 | — | — | — |
| Responders, Week 52 | 55.0 | 87.5 | 68.8 | 50.0 | 100 | — | — | — |
| Non-responders, Week 20 | 43.8 | 60.0 | 41.2 | 39.1 | 75.0 | 20.0 | 33.3 | 50.0 |
| Non-responders, Week 28 | 40.6 | 60.0 | 29.4 | 26.1 | 50.0 | 20.0 | 22.2 | 50.0 |
| Non-responders, Week 36 | 28.1 | 40.0 | 26.5 | 17.4 | 50.0 | 20.0 | 33.3 | 25.0 |
| Non-responders, Week 44 | 25.0 | 30.0 | 26.5 | 21.7 | 37.5 | 40.0 | 33.3 | 50.0 |
| Non-responders, Week 52 | 21.9 | 30.0 | 26.5 | 13.0 | 37.5 | 40.0 | 33.3 | 50.0 |
| Clinical responders, Week 20 | 78.1 | 100 | 93.1 | 78.9 | 100 | 100 | 25.0 | 100 |
| Clinical responders, Week 28 | 78.1 | 78.6 | 69.0 | 57.9 | 66.7 | 100 | 25.0 | 100 |
| Clinical responders, Week 36 | 65.6 | 78.6 | 65.5 | 47.4 | 83.3 | 100 | 25.0 | 100 |
| Clinical responders, Week 44 | 50.0 | 71.4 | 72.4 | 42.1 | 50.0 | 100 | 25.0 | 100 |
| Clinical responders, Week 52 | 50.0 | 71.4 | 62.1 | 42.1 | 66.7 | 100 | 25.0 | 100 |
| Non-clinical responders, Week 20 | 30.0 | 0 | 14.3 | 14.3 | 33.3 | 0 | 40.0 | 33.3 |
| Non-clinical responders, Week 28 | 25.0 | 25.0 | 14.3 | 7.1 | 0 | 0 | 20.0 | 33.3 |
| Non-clinical responders, Week 36 | 15.0 | 25.0 | 9.5 | 0 | 0 | 0 | 40.0 | 0 |
| Non-clinical responders, Week 44 | 10.0 | 0 | 4.8 | 7.1 | 0 | 25.0 | 40.0 | 33.3 |
| Non-clinical responders, Week 52 | 10.0 | 0 | 9.5 | 0 | 0 | 25.0 | 40.0 | 33.3 |
Enhanced clinical response was defined as average daily stool frequency at least 60% reduction from Induction Baseline and average daily abdominal pain not worse than Induction Baseline OR average daily abdominal pain at least 35% reduction from Induction Baseline and average daily stool frequency not worse than Induction Baseline or modified clinical remission (average daily stool frequency ≤ 2.8 and not worse than Induction baseline AND average daily abdominal pain ≤ 1.0 and not worse than Induction baseline). The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders, Week 20 | 70.0 | 87.5 | 100 | 70.0 | 100 | — | — | — |
| Responders, Week 28 | 80.0 | 75.0 | 81.3 | 60.0 | 0 | — | — | — |
| Responders, Week 36 | 75.0 | 100 | 75.0 | 40.0 | 100 | — | — | — |
| Responders, Week 44 | 50.0 | 62.5 | 75.0 | 40.0 | 0 | — | — | — |
| Responders, Week 52 | 50.0 | 87.5 | 68.8 | 50.0 | 100 | — | — | — |
| Non-responders, Week 20 | 34.4 | 50.0 | 38.2 | 26.1 | 50.0 | 20.0 | 33.3 | 25.0 |
| Non-responders, Week 28 | 37.5 | 60.0 | 29.4 | 21.7 | 70.0 | 20.0 | 22.2 | 50.0 |
| Non-responders, Week 36 | 28.1 | 40.0 | 26.5 | 17.4 | 50.0 | 20.0 | 33.3 | 25.0 |
| Non-responders, Week 44 | 21.9 | 30.0 | 23.5 | 21.7 | 37.5 | 20.0 | 33.3 | 50.0 |
| Non-responders, Week 52 | 21.9 | 30.0 | 26.5 | 13.0 | 37.5 | 40.0 | 33.3 | 50.0 |
| Clinical responders, Week 20 | 62.5 | 85.7 | 93.1 | 63.2 | 83.3 | 100 | 25.0 | 100 |
| Clinical responders, Week 28 | 71.9 | 78.6 | 69.0 | 57.9 | 66.7 | 100 | 25.0 | 100 |
| Clinical responders, Week 36 | 65.6 | 78.6 | 65.5 | 42.1 | 83.3 | 100 | 25.0 | 100 |
| Clinical responders, Week 44 | 50.0 | 57.1 | 65.5 | 42.1 | 50.0 | 100 | 25.0 | 100 |
| Clinical responders, Week 52 | 46.9 | 71.4 | 62.1 | 42.1 | 66.7 | 100 | 25.0 | 100 |
| Clinical non-responders, Week 20 | 25.0 | 0 | 9.5 | 7.1 | 0 | 0 | 40.0 | 0 |
| Clinical non-responders, Week 28 | 25.0 | 25.0 | 14.3 | 0 | 0 | 0 | 20.0 | 33.3 |
| Clinical non-responders, Week 36 | 15.0 | 25.0 | 9.5 | 0 | 0 | 0 | 40.0 | 0 |
| Clinical non-responders, Week 44 | 5.0 | 0 | 4.8 | 7.1 | 0 | 0 | 40.0 | 33.3 |
| Clinical non-responders, Week 52 | 10.0 | 0 | 9.5 | 0 | 0 | 25.0 | 40.0 | 33.3 |
Enhanced clinical response was defined as average daily stool frequency at least 60% reduction from Induction Baseline and average daily abdominal pain not worse than Induction Baseline or average daily abdominal pain at least 35% reduction from Induction Baseline and average daily stool frequency not worse than Induction Baseline or modified clinical remission (average daily stool frequency ≤ 2.8 and not worse than Induction baseline AND average daily abdominal pain ≤ 1.0 and not worse than Induction baseline). The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders, Week 20 | 70.0 | 100 | 100 | 66.7 | — | — | — | — |
| Responders, Week 28 | 80.0 | 71.4 | 81.3 | 55.6 | — | — | — | — |
| Responders, Week 36 | 75.0 | 100 | 75.0 | 33.3 | — | — | — | — |
| Responders, Week 44 | 50.0 | 71.4 | 75.0 | 33.3 | — | — | — | — |
| Responders, Week 52 | 50.0 | 85.7 | 68.8 | 44.4 | — | — | — | — |
| Non-responders, Week 20 | 50.0 | 83.3 | 83.3 | 57.1 | 100 | 100 | 50.0 | 100 |
| Non-responders, Week 28 | 70.0 | 83.3 | 58.3 | 57.1 | 100 | 100 | 50.0 | 100 |
| Non-responders, Week 36 | 50.0 | 50.0 | 58.3 | 57.1 | 100 | 100 | 50.0 | 100 |
| Non-responders, Week 44 | 50.0 | 50.0 | 58.3 | 57.1 | 75.0 | 100 | 50.0 | 100 |
| Non-responders, Week 52 | 40.0 | 50.0 | 58.3 | 42.9 | 75.0 | 100 | 50.0 | 100 |
| Clinical Responders, Week 20 | 63.3 | 92.3 | 92.9 | 66.7 | 100 | 100 | 50.0 | 100 |
| Clinical Responders, Week 28 | 76.7 | 76.9 | 71.4 | 60.0 | 100 | 100 | 50.0 | 100 |
| Clinical Responders, Week 36 | 66.7 | 76.9 | 67.9 | 46.7 | 100 | 100 | 50.0 | 100 |
| Clinical Responders, Week 44 | 50.0 | 61.5 | 67.9 | 46.7 | 75.0 | 100 | 50.0 | 100 |
| Clinical Responders, Week 52 | 46.7 | 69.2 | 64.3 | 46.7 | 75.0 | 100 | 50.0 | 100 |
| Clinical Non-responders, Week 20 | — | — | — | 0 | — | — | — | — |
| Clinical Non-responders, Week 28 | — | — | — | 0 | — | — | — | — |
| Clinical Non-responders, Week 36 | — | — | — | 0 | — | — | — | — |
| Clinical Non-responders, Week 44 | — | — | — | 0 | — | — | — | — |
| Clinical Non-responders, Week 52 | — | — | — | 0 | — | — | — | — |
Clinical remission was defined as average daily stool frequency \<= 1.5 and not worse than Induction Baseline AND average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction |
|---|---|---|---|---|
| Responders, Week 20 | 44.4 | 16.7 | 37.5 | 20.0 |
| Responders, Week 28 | 55.6 | 16.7 | 50.0 | 40.0 |
| Responders, Week 36 | 44.4 | 16.7 | 50.0 | 20.0 |
| Responders, Week 44 | 44.4 | 0 | 50.0 | 40.0 |
| Responders, Week 52 | 33.3 | 33.3 | 50.0 | 20.0 |
| Non-responders, Week 20 | 21.4 | 40.0 | 6.7 | 11.1 |
| Non-responders, Week 28 | 21.4 | 40.0 | 6.7 | 22.2 |
| Non-responders, Week 36 | 21.4 | 20.0 | 0 | 22.2 |
| Non-responders, Week 44 | 14.3 | 20.0 | 6.7 | 11.1 |
| Non-responders, Week 52 | 7.1 | 20.0 | 13.3 | 22.2 |
| Clinical responders, Week 20 | 41.2 | 30.0 | 26.7 | 22.2 |
| Clinical responders, Week 28 | 47.1 | 30.0 | 33.3 | 44.4 |
| Clinical responders, Week 36 | 41.2 | 20.0 | 26.7 | 33.3 |
| Clinical responders, Week 44 | 35.3 | 10.0 | 33.3 | 33.3 |
| Clinical responders, Week 52 | 23.5 | 30.0 | 40.0 | 33.3 |
| Clinical non-responders, Week 20 | 0 | 0 | 0 | 0 |
| Clinical non-responders, Week 28 | 0 | 0 | 0 | 0 |
| Clinical non-responders, Week 36 | 0 | 0 | 0 | 0 |
| Clinical non-responders, Week 44 | 0 | 0 | 0 | 0 |
| Clinical non-responders, Week 52 | 0 | 0 | 0 | 0 |
CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A score below 150 indicates remission.
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders, Week 20 | 50.0 | 50.0 | 75.0 | 0 | — | — | — | — |
| Responders, Week 28 | 50.0 | 50.0 | 50.0 | 20.0 | — | — | — | — |
| Responders, Week 36 | 50.0 | 100 | 50.0 | 0 | — | — | — | — |
| Responders, Week 44 | 37.5 | 50.0 | 50.0 | 20.0 | — | — | — | — |
| Responders, Week 52 | 50.0 | 100 | 62.5 | 0 | — | — | — | — |
| Non-responders, Week 20 | 13.3 | 40.0 | 8.3 | 0 | 0 | — | 0 | 0 |
| Non-responders, Week 28 | 6.7 | 40.0 | 16.7 | 11.1 | 0 | — | 0 | 0 |
| Non-responders, Week 36 | 13.3 | 40.0 | 8.3 | 11.1 | 0 | — | 0 | 0 |
| Non-responders, Week 44 | 26.7 | 40.0 | 25.0 | 11.1 | 0 | — | 0 | 0 |
| Non-responders, Week 52 | 20.0 | 40.0 | 25.0 | 11.1 | 0 | — | 0 | 0 |
| Clinical responders, Week 20 | 40.0 | 50.0 | 50.0 | 0 | 0 | — | 0 | — |
| Clinical responders, Week 28 | 33.3 | 50.0 | 42.9 | 25.0 | 0 | — | 0 | — |
| Clinical responders, Week 36 | 40.0 | 66.7 | 35.7 | 12.5 | 0 | — | 0 | — |
| Clinical responders, Week 44 | 40.0 | 50.0 | 50.0 | 25.0 | 0 | — | 0 | — |
| Clinical responders, Week 52 | 46.7 | 66.7 | 57.1 | 12.5 | 0 | — | 0 | — |
| Clinical non-responders, Week 20 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Clinical non-responders, Week 28 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Clinical non-responders, Week 36 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Clinical non-responders, Week 44 | 12.5 | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Clinical non-responders, Week 52 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
Steroid-free remission at Week 52 was defined as both endoscopic remission at Week 52 and clinical remission at Week 52. Endoscopic remission: SES-CD ≤ 4 and at least 2 point reduction versus Induction Baseline and no subscore \> 1 in any individual variable. Clinical remission: Average daily stool frequency ≤ 1.5 and not worse than baseline AND average daily abdominal pain ≤ 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). See SES-CD description details in the first primary endpoint description of this record.
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders | 25.0 | 0 | 37.5 | 0 | — | — | — | — |
| Non-responders | 0 | 0 | 0 | 11.1 | 0 | — | 0 | 0 |
| Clinical Responders | 13.3 | 0 | 21.4 | 12.5 | 0 | — | 0 | — |
| Clinical non-responders | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
Steroid-free clinical remission was defined as average daily stool frequency \<= 1.5 and not worse than Induction Baseline AND average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders, Week 20 | 50.0 | 50.0 | 50.0 | 0 | — | — | — | — |
| Responders, Week 28 | 37.5 | 50.0 | 50.0 | 20.0 | — | — | — | — |
| Responders, Week 36 | 37.5 | 100 | 62.5 | 0 | — | — | — | — |
| Responders, Week 44 | 37.5 | 0 | 62.5 | 20.0 | — | — | — | — |
| Responders, Week 52 | 25.0 | 100 | 62.5 | 0 | — | — | — | — |
| Non-responders, Week 20 | 13.3 | 40.0 | 0 | 0 | 0 | — | 0 | 0 |
| Non-responders, Week 28 | 6.7 | 40.0 | 16.7 | 11.1 | 0 | — | 0 | 0 |
| Non-responders, Week 36 | 6.7 | 20.0 | 0 | 11.1 | 0 | — | 0 | 0 |
| Non-responders, Week 44 | 20.0 | 40.0 | 0 | 11.1 | 0 | — | 0 | 0 |
| Non-responders, Week 52 | 13.3 | 20.0 | 8.3 | 11.1 | 0 | — | 0 | 0 |
| Clinical responders, Week 20 | 40.0 | 50.0 | 28.6 | 0 | 0 | — | 0 | — |
| Clinical responders, Week 28 | 26.7 | 50.0 | 42.9 | 25.0 | 0 | — | 0 | — |
| Clinical responders, Week 36 | 26.7 | 50.0 | 35.7 | 12.5 | 0 | — | 0 | — |
| Clinical responders, Week 44 | 40.0 | 33.3 | 35.7 | 25.0 | 0 | — | 0 | — |
| Clinical responders, Week 52 | 26.7 | 50.0 | 42.9 | 12.5 | 0 | — | 0 | — |
| Clinical non-responders, Week 20 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Clinical non-responders, Week 28 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Clinical non-responders, Week 36 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Clinical non-responders, Week 44 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Clinical non-responders, Week 52 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
Steroid-free modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than Induction Baseline AND average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders, Week 20 | 33.3 | 50.0 | 62.5 | 20.0 | — | — | — | — |
| Responders, Week 28 | 50.0 | 50.0 | 62.5 | 20.0 | — | — | — | — |
| Responders, Week 36 | 50.0 | 100 | 62.5 | 0 | — | — | — | — |
| Responders, Week 44 | 33.3 | 50.0 | 62.5 | 20.0 | — | — | — | — |
| Responders, Week 52 | 33.3 | 100 | 62.5 | 0 | — | — | — | — |
| Non-responders, Week 20 | 8.3 | 40.0 | 8.3 | 0 | 0 | — | 0 | 0 |
| Non-responders, Week 28 | 16.7 | 40.0 | 16.7 | 12.5 | 0 | — | 0 | 0 |
| Non-responders, Week 36 | 8.3 | 20.0 | 8.3 | 12.5 | 0 | — | 0 | 0 |
| Non-responders, Week 44 | 16.7 | 40.0 | 0 | 12.5 | 0 | — | 0 | 0 |
| Non-responders, Week 52 | 8.3 | 20.0 | 16.7 | 12.5 | 0 | — | 0 | 0 |
| Clinical responders, Week 20 | 25.0 | 50.0 | 42.9 | 14.3 | 0 | — | 0 | — |
| Clinical responders, Week 28 | 41.7 | 50.0 | 50.0 | 28.6 | 0 | — | 0 | — |
| Clinical responders, Week 36 | 33.3 | 50.0 | 42.9 | 14.3 | 0 | — | 0 | — |
| Clinical responders, Week 44 | 33.3 | 50.0 | 35.7 | 28.6 | 0 | — | 0 | — |
| Clinical responders, Week 52 | 25.0 | 50.0 | 50.0 | 14.3 | 0 | — | 0 | — |
| Clinical non-responders, Week 20 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Clinical non-responders, Week 28 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Clinical non-responders, Week 36 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Clinical non-responders, Week 44 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Clinical non-responders, Week 52 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
Steroid-free endoscopic remission was defined as SES-CD \<= 4 and at least 2 points reduction versus Induction Baseline and no subscore \> 1 in any individual variable. Details of the SES-CD scale are provided in the description of the first primary endpoint.
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders | 25.0 | 0 | 50.0 | 0 | — | — | — | — |
| Non-responders | 0 | 20.0 | 8.3 | 11.1 | 0 | — | 0 | 0 |
| Clinical responders | 13.3 | 16.7 | 35.7 | 12.5 | 0 | — | 0 | — |
| Clinical non-responders | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A score below 150 indicates remission.
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders, Week 20 | 65.0 | 50.0 | 75.0 | 50.0 | 0 | — | — | — |
| Responders, Week 28 | 75.0 | 25.0 | 62.5 | 60.0 | 0 | — | — | — |
| Responders, Week 36 | 70.0 | 75.0 | 62.5 | 30.0 | 0 | — | — | — |
| Responders, Week 44 | 45.0 | 37.5 | 62.5 | 40.0 | 0 | — | — | — |
| Responders, Week 52 | 55.0 | 50.0 | 68.8 | 40.0 | 0 | — | — | — |
| Non-responders, Week 20 | 28.1 | 50.0 | 17.6 | 8.7 | 75.0 | 20.0 | 11.1 | 50.0 |
| Non-responders, Week 28 | 15.6 | 40.0 | 17.6 | 13.0 | 37.5 | 20.0 | 22.2 | 50.0 |
| Non-responders, Week 36 | 15.6 | 30.0 | 14.7 | 13.0 | 37.5 | 20.0 | 33.3 | 50.0 |
| Non-responders, Week 44 | 18.8 | 30.0 | 17.6 | 8.7 | 25.0 | 20.0 | 33.3 | 25.0 |
| Non-responders, Week 52 | 9.4 | 30.0 | 20.6 | 13.0 | 25.0 | 40.0 | 33.3 | 50.0 |
| Clinical responders, Week 20 | 59.4 | 64.3 | 51.7 | 36.8 | 83.3 | 100 | 0 | 100 |
| Clinical responders, Week 28 | 56.3 | 42.9 | 48.3 | 47.4 | 50.0 | 100 | 25.0 | 100 |
| Clinical responders, Week 36 | 59.4 | 64.3 | 44.8 | 31.6 | 50.0 | 100 | 25.0 | 100 |
| Clinical responders, Week 44 | 40.6 | 42.9 | 55.2 | 31.6 | 33.3 | 100 | 25.0 | 100 |
| Clinical responders, Week 52 | 43.8 | 50.0 | 55.2 | 36.8 | 33.3 | 100 | 25.0 | 100 |
| Clinical non- responders, Week 20 | 15.0 | 0 | 14.3 | 0 | 33.3 | 0 | 20.0 | 33.3 |
| Clinical non- responders, Week 28 | 10.0 | 0 | 9.5 | 0 | 0 | 0 | 20.0 | 33.3 |
| Clinical non- responders, Week 36 | 0 | 0 | 9.5 | 0 | 0 | 0 | 40.0 | 33.3 |
| Clinical non- responders, Week 44 | 10.0 | 0 | 0 | 0 | 0 | 0 | 40.0 | 0 |
| Clinical non- responders, Week 52 | 0 | 0 | 9.5 | 0 | 0 | 25.0 | 40.0 | 33.3 |
CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A 70-point decrease in the CDAI index refers to improvement in the disease activity from Baseline.
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders, Week 20 | 80.0 | 100 | 93.8 | 60.0 | 100 | — | — | — |
| Responders, Week 28 | 85.0 | 62.5 | 68.8 | 60.0 | 0 | — | — | — |
| Responders, Week 36 | 75.0 | 100 | 75.0 | 50.0 | 100 | — | — | — |
| Responders, Week 44 | 60.0 | 87.5 | 81.3 | 40.0 | 100 | — | — | — |
| Responders, Week 52 | 55.0 | 75.0 | 75.0 | 40.0 | 100 | — | — | — |
| Non-responders, Week 20 | 46.9 | 70.0 | 47.1 | 34.8 | 75.0 | 20.0 | 22.2 | 50.0 |
| Non-responders, Week 28 | 34.4 | 60.0 | 29.4 | 30.4 | 50.0 | 20.0 | 33.3 | 50.0 |
| Non-responders, Week 36 | 28.1 | 50.0 | 26.5 | 17.4 | 50.0 | 20.0 | 33.3 | 50.0 |
| Non-responders, Week 44 | 25.0 | 30.0 | 29.4 | 26.1 | 37.5 | 40.0 | 33.3 | 25.0 |
| Non-responders, Week 52 | 12.5 | 40.0 | 26.5 | 17.4 | 37.5 | 40.0 | 33.3 | 50.0 |
| Clinical responders, Week 20 | 75.0 | 100 | 89.7 | 63.2 | 100 | 100 | 0 | 100 |
| Clinical responders, Week 28 | 75.0 | 71.4 | 58.6 | 57.9 | 66.7 | 100 | 25.0 | 100 |
| Clinical responders, Week 36 | 65.6 | 85.7 | 62.1 | 42.1 | 83.3 | 100 | 25.0 | 100 |
| Clinical responders, Week 44 | 56.3 | 71.4 | 72.4 | 42.1 | 66.7 | 100 | 25.0 | 100 |
| Clinical responders, Week 52 | 46.9 | 71.4 | 62.1 | 36.8 | 66.7 | 100 | 25.0 | 100 |
| Clinical non-responders, Week 20 | 35.0 | 25.0 | 23.8 | 14.3 | 33.3 | 0 | 40.0 | 33.3 |
| Clinical non-responders, Week 28 | 20.0 | 25.0 | 19.0 | 14.3 | 0 | 0 | 40.0 | 33.3 |
| Clinical non-responders, Week 36 | 15.0 | 25.0 | 14.3 | 7.1 | 0 | 0 | 40.0 | 33.3 |
| Clinical non-responders, Week 44 | 10.0 | 0 | 9.5 | 14.3 | 0 | 25.0 | 40.0 | 0 |
| Clinical non-responders, Week 52 | 0 | 0 | 14.3 | 7.1 | 0 | 25.0 | 40.0 | 33.3 |
| mcg/g | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders, Week 28 | -153.4 ± 2722.96 | -532.0 ± 519.42 | -2878.6 ± 2584.43 | -3563.7 ± 4747.26 | -194.0 ± NA | — | — | — |
| Responders, Week 52 | -51.9 ± 2650.98 | -524.1 ± 521.31 | -3047.5 ± 2509.27 | -2371.8 ± 2786.97 | -44.0 ± NA | — | — | — |
| Non-responders, Week 28 | -150.3 ± 958.76 | -148.3 ± 1315.46 | -834.5 ± 3011.51 | -850.2 ± 1821.34 | -16.5 ± 304.33 | -121.0 ± 395.16 | -326.8 ± 817.71 | 760.5 ± 1075.51 |
| Non-responders, Week 52 | -87.2 ± 1494.35 | 88.3 ± 1689.67 | -704.0 ± 2801.08 | -562.8 ± 1738.58 | -8.3 ± 344.29 | -121.0 ± 395.16 | -434.0 ± 1030.64 | 760.5 ± 1075.51 |
| Clinical responders, Week 28 | -226.2 ± 2261.16 | -424.5 ± 1102.22 | -2794.6 ± 3018.26 | -2099.3 ± 3083.34 | -65.0 ± 316.06 | -694.0 ± NA | 117.5 ± 166.17 | — |
| Clinical responders, Week 52 | 1.0 ± 2457.22 | -239.3 ± 1443.14 | -2617.4 ± 3232.04 | -1510.3 ± 2773.90 | -44.3 ± 350.61 | -694.0 ± NA | 117.5 ± 166.17 | — |
| Clinical non-responders, Week 28 | 3.7 ± 766.69 | -30.7 ± 32.65 | 606.0 ± 1133.70 | 183.7 ± 443.97 | 0.0 ± NA | 70.0 ± 123.85 | -771.0 ± 1090.36 | 760.5 ± 1075.51 |
| Clinical non-responders, Week 52 | -220.2 ± 514.97 | -30.7 ± 32.65 | 213.3 ± 802.34 | 183.7 ± 443.97 | 0.0 ± NA | 70.0 ± 123.85 | -985.5 ± 1393.71 | 760.5 ± 1075.51 |
| mg/L | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders, Week 20 | -9.5 ± 21.77 | -9.4 ± 11.14 | -20.8 ± 19.78 | 4.1 ± 36.50 | -3.1 ± NA | — | — | — |
| Responders, Week 28 | -6.0 ± 22.53 | -3.6 ± 16.12 | -21.8 ± 17.93 | 7.0 ± 35.65 | -4.2 ± NA | — | — | — |
| Responders, Week 36 | -1.8 ± 25.57 | -7.2 ± 10.86 | -22.5 ± 18.01 | 5.6 ± 35.87 | -4.0 ± NA | — | — | — |
| Responders, Week 44 | -5.4 ± 22.95 | -8.5 ± 12.18 | -21.5 ± 19.78 | 5.8 ± 35.77 | 10.6 ± NA | — | — | — |
| Responders, Week 52 | -4.3 ± 22.68 | -7.0 ± 12.66 | -20.4 ± 18.76 | 6.2 ± 35.82 | 0.4 ± NA | — | — | — |
| Non-responders, Week 20 | -2.2 ± 9.72 | -1.6 ± 8.24 | -8.5 ± 25.00 | -8.0 ± 18.77 | 0.3 ± 10.89 | -1.0 ± 0.97 | -6.8 ± 8.82 | -1.5 ± 2.39 |
| Non-responders, Week 28 | -3.0 ± 9.61 | -0.2 ± 5.92 | -6.4 ± 27.03 | -6.5 ± 20.14 | 0.3 ± 9.78 | -1.1 ± 1.06 | -5.9 ± 6.58 | 3.8 ± 9.55 |
| Non-responders, Week 36 | -0.7 ± 8.86 | 5.2 ± 15.34 | -7.3 ± 24.87 | 0.8 ± 45.98 | 3.3 ± 8.88 | 0.5 ± 0.41 | -3.7 ± 7.80 | 8.3 ± 12.71 |
| Non-responders, Week 44 | -1.3 ± 7.82 | 11.1 ± 33.68 | -4.1 ± 27.93 | 0.9 ± 45.88 | 3.0 ± 9.51 | -0.9 ± 0.87 | -4.1 ± 7.12 | 5.5 ± 9.39 |
| Non-responders, Week 52 | -1.2 ± 8.67 | 2.8 ± 17.81 | -3.4 ± 32.58 | 1.3 ± 45.26 | 4.7 ± 11.50 | -0.2 ± 0.42 | -5.1 ± 8.52 | 2.5 ± 9.89 |
| Clinical responders, Week 20 | -7.1 ± 18.6 | -6.9 ± 10.80 | -18.0 ± 29.20 | -3.0 ± 31.35 | -3.8 ± 5.59 | -2.2 ± NA | -9.5 ± 12.15 | -4.4 ± NA |
| Clinical responders, Week 28 | -5.4 ± 19.26 | -2.0 ± 12.93 | -19.2 ± 30.13 | 0.0 ± 32.17 | -4.0 ± 4.77 | -2.3 ± NA | -6.1 ± 6.32 | -5.3 ± NA |
| Clinical responders, Week 36 | -0.8 ± 20.85 | -0.5 ± 16.69 | -18.6 ± 28.62 | 9.1 ± 56.33 | 0.1 ± 5.93 | 0.4 ± NA | -3.2 ± 9.54 | -4.9 ± NA |
| Clinical responders, Week 44 | -3.5 ± 18.87 | 3.0 ± 31.54 | -15.3 ± 32.75 | 9.3 ± 56.18 | 2.2 ± 7.92 | -1.5 ± NA | -1.8 ± 7.26 | -3.9 ± NA |
| Clinical responders, Week 52 | -2.8 ± 18.91 | -2.1 ± 18.36 | -13.9 ± 37.06 | 10.2 ± 55.66 | 2.7 ± 10.77 | -0.7 ± NA | -4.2 ± 11.29 | -4.6 ± NA |
| Clinical non-responders, Week 20 | -1.7 ± 10.51 | 1.4 ± 2.83 | -4.9 ± 8.36 | -6.2 ± 15.35 | 10.9 ± 15.47 | -0.6 ± 0.71 | -4.8 ± 6.69 | -0.5 ± 1.68 |
| Clinical non-responders, Week 28 | -2.2 ± 7.71 | -0.6 ± 1.43 | -0.6 ± 6.82 | -5.7 ± 15.26 | 7.3 ± 12.63 | -0.7 ± 0.81 | -5.8 ± 7.73 | 6.8 ± 9.10 |
| Clinical non-responders, Week 36 | -1.7 ± 8.94 | 0.4 ± 0.51 | -3.4 ± 8.04 | -6.1 ± 13.28 | 7.3 ± 12.63 | 0.6 ± 0.50 | -4.1 ± 7.77 | 12.7 ± 11.20 |
| Clinical non-responders, Week 44 | -1.9 ± 7.83 | 0.4 ± 0.51 | -2.3 ± 9.37 | -6.2 ± 13.15 | 7.3 ± 12.63 | -0.7 ± 0.95 | -5.8 ± 7.55 | 8.6 ± 8.55 |
| Clinical non-responders, Week 52 | -1.9 ± 8.11 | 0.4 ± 0.51 | -2.2 ± 9.28 | -6.3 ± 11.71 | 7.3 ± 12.63 | 0.0 ± 0.33 | -5.8 ± 7.66 | 4.9 ± 10.60 |
The IBDQ is a disease-specific instrument composed of 32 Likert-scaled items. The total score ranges from 32 to 224 using the 7-point response options, with higher scores indicating better health-related quality of life. The IBDQ scale contains 4 component subscales: bowel symptoms, systemic symptoms, emotional function, and social function. Each subscale can be computed with total scores ranging from 10 to 70, 5 to 35, 12 to 84, and 5 to 35, respectively.
| units on a scale | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders | 43.9 ± 38.06 | 56.4 ± 14.52 | 82.3 ± 35.59 | 45.3 ± 49.89 | -5.0 ± NA | — | — | — |
| Non-responders | 20.8 ± 43.58 | 26.0 ± 33.14 | 25.9 ± 47.05 | 2.9 ± 35.25 | 4.8 ± 16.42 | 35.5 ± 28.78 | 45.4 ± 36.16 | 41.5 ± 24.75 |
| Clinical responders | 42.8 ± 44.13 | 46.6 ± 27.76 | 70.7 ± 46.99 | 26.6 ± 53.11 | 4.8 ± 18.70 | 68.0 ± NA | 34.5 ± 4.95 | 24.0 ± NA |
| Clinical non-responders | 9.4 ± 31.46 | 13.5 ± 19.09 | 9.8 ± 30.81 | -1.5 ± 5.81 | 0.0 ± 0.00 | 24.6 ± 23.17 | 52.7 ± 49.03 | 59.0 ± NA |
The EQ-5D is a standardized instrument for use as a measure of health-related quality of life. The EQ-5D Index Score has five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Health states are converted into a weighted health state index. These weights lie on a scale on which full health has a value of 1 and dead has a value of 0. A positive change represents an improvement in health-related quality of life.
| units on a scale | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders | 0.1350 ± 0.1473 | 0.1673 ± 0.1090 | 0.2274 ± 0.1524 | 0.0122 ± 0.1276 | 0.3260 ± NA | — | — | — |
| Non-responders | 0.0208 ± 0.2231 | 0.0697 ± 0.2091 | 0.1090 ± 0.1791 | 0.0449 ± 0.1008 | 0.1288 ± 0.1674 | 0.1125 ± 0.2210 | 0.1542 ± 0.2377 | 0.1187 ± 0.1128 |
| Clinical responders | 0.1435 ± 0.1461 | 0.1334 ± 0.1740 | 0.2306 ± 0.1840 | 0.0587 ± 0.1298 | 0.2198 ± 0.1615 | 0.4325 ± NA | 0.1758 ± 0.3559 | 0.1316 ± NA |
| Clinical non-responders | -0.0577 ± 0.2225 | 0.0455 ± 0.0643 | 0.0330 ± 0.0677 | -0.0079 ± 0.0228 | 0.0000 ± 0.0000 | 0.0058 ± 0.0708 | 0.1325 ± 0.1148 | 0.1122 ± 0.1587 |
The EQ-5D is a standardized instrument for use as a measure of health-related quality of life. The EQ-5D VAS is a 20-cm scale with endpoints labeled "best imaginable health" and "worst imaginable health" anchored at 100 and 0, respectively. A positive change represents an improvement in health-related quality of life.
| units on a scale | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders | 12.9 ± 14.65 | 26.9 ± 12.80 | 34.8 ± 22.55 | 5.0 ± 17.80 | 5.0 ± NA | — | — | — |
| Non-responders | 12.3 ± 24.79 | 11.9 ± 18.73 | 13.9 ± 27.81 | 4.7 ± 14.22 | 12.2 ± 16.01 | 17.5 ± 16.58 | 20.3 ± 21.23 | 0.0 ± 15.00 |
| Clinical responders | 18.2 ± 19.19 | 22.2 ± 17.16 | 36.1 ± 26.19 | 8.1 ± 17.95 | 15.6 ± 15.63 | 40.0 ± NA | 11.7 ± 16.07 | -15.0 ± NA |
| Clinical non-responders | 3.7 ± 21.79 | 5.0 ± 7.07 | 0.8 ± 11.72 | -1.0 ± 4.24 | 0.0 ± 0.00 | 10.0 ± 8.66 | 29.0 ± 25.36 | 7.5 ± 10.61 |
Presented as percentage of participants with given number of EIMs at Baseline (BL) and Week (Wk) 52. EIMs of Crohn's disease included anemia, autoimmune hepatitis, axial arthropathy, bronchiectasis, chronic obstructive pulmonary disease, episcleritis, erythema nodosum, iritis, nephrolithiasis, oral aphthous ulcers, peripheral arthropathy, primary sclerosing cholangitis, pyoderma gangrenosum, Sweet's syndrome, uveitis, and venous thromboembolism.
| percentage of participants | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: 12 mg BID | Double Blind Induction Phase: 24 mg BID | Double Blind Induction Phase: 24 mg QD |
|---|---|---|---|---|---|---|
| 0 at BL/0 at Wk 52 | 85.7 | 100 | 86.4 | 76.0 | 73.3 | 85.0 |
| 0 at BL/1 at Wk 52 | 7.1 | 0 | 9.1 | 16.0 | 13.3 | 10.0 |
| 0 at BL/2 at Wk 52 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 at BL/3 at Wk 52 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 at BL/4 at Wk 52 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 at BL/5 at Wk 52 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 at BL/missing at Wk 52 | 7.1 | 0 | 4.5 | 8.0 | 13.3 | 5.0 |
| 1 at BL/0 at Wk 52 | 42.9 | 31.6 | 40.0 | 62.5 | 50.0 | 54.5 |
| 1 at BL/1 at Wk 52 | 50.0 | 57.9 | 60.0 | 12.5 | 33.3 | 36.4 |
| 1 at BL/2 at Wk 52 | 7.1 | 5.3 | 0 | 25.0 | 11.1 | 9.1 |
| 1 at BL/3 at Wk 52 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 at BL/4 at Wk 52 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 at BL/5 at Wk 52 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 at BL/missing at Wk 52 | 0 | 5.3 | 0 | 0 | 5.6 | 0 |
| 2 at BL/0 at Wk 52 | 20.0 | 50.0 | 0 | 33.3 | — | 25.0 |
| 2 at BL/1 at Wk 52 | 0 | 25.0 | 66.7 | 33.3 | — | 25.0 |
| 2 at BL/2 at Wk 52 | 60.0 | 25.0 | 33.3 | 33.3 | — | 50.0 |
| 2 at BL/3 at Wk 52 | 0 | 0 | 0 | 0 | — | 0 |
| 2 at BL/4 at Wk 52 | 0 | 0 | 0 | 0 | — | 0 |
| 2 at BL/5 at Wk 52 | 0 | 0 | 0 | 0 | — | 0 |
| 2 at BL/missing at Wk 52 | 20.0 | 0 | 0 | 0 | — | 0 |
| 3 at BL/0 at Wk 52 | 0 | 50.0 | 0 | — | 66.7 | — |
| 3 at BL/1 at Wk 52 | 50.0 | 50.0 | 0 | — | 0 | — |
| 3 at BL/2 at Wk 52 | 0 | 0 | 100 | — | 33.3 | — |
| 3 at BL/3 at Wk 52 | 0 | 0 | 0 | — | 0 | — |
| 3 at BL/4 at Wk 52 | 50.0 | 0 | 0 | — | 0 | — |
| 3 at BL/5 at Wk 52 | 0 | 0 | 0 | — | 0 | — |
| 3 at BL/missing at Wk 52 | 0 | 0 | 0 | — | 0 | — |
| 4 at BL/0 at Wk 52 | 0 | 100 | 0 | — | — | — |
| 4 at BL/1 at Wk 52 | 0 | 0 | 0 | — | — | — |
| 4 at BL/2 at Wk 52 | 0 | 0 | 0 | — | — | — |
| 4 at BL/3 at Wk 52 | 0 | 0 | 0 | — | — | — |
| 4 at BL/4 at Wk 52 | 100 | 0 | 0 | — | — | — |
| 4 at BL/5 at Wk 52 | 0 | 0 | 0 | — | — | — |
| 4 at BL/missing at Wk 52 | 0 | 0 | 100 | — | — | — |
| 5 at BL/0 at Wk 52 | 0 | — | — | — | — | — |
| 5 at BL/1 at Wk 52 | 0 | — | — | — | — | — |
| 5 at BL/2 at Wk 52 | 0 | — | — | — | — | — |
| 5 at BL/3 at Wk 52 | 0 | — | — | — | — | — |
| 5 at BL/4 at Wk 52 | 0 | — | — | — | — | — |
| 5 at BL/5 at Wk 52 | 100 | — | — | — | — | — |
| 5 at BL/missing at Wk 52 | 0 | — | — | — | — | — |
Remission at Week 52 is defined as endoscopic remission at Week 52 AND clinical remission at Week 52. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders | 50.0 | — | 0 | — | — | — | — | — |
| Non-responders | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Clinical responders | 25.0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Clinical non-responders | 0 | 0 | 0 | 0 | — | 0 | 0 | — |
Modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than induction baseline AND average daily abdominal pain \<= 1.0 and not worse than induction baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).
| percentage of participants | Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction | Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction | Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction | Upadacitinib 3 mg BID in Extension/ Placebo in Induction | Upadacitinib 6 mg BID in Extension/ Placebo in Induction | Upadacitinib 12 mg BID in Extension/ Placebo in Induction | Upadacitinib 24 mg QD in Extension/ Placebo in Induction |
|---|---|---|---|---|---|---|---|---|
| Responders | 66.7 | — | 0 | — | — | — | — | — |
| Non-responders | 0 | 33.3 | 0 | 0 | 50.0 | 0 | 0 | — |
| Clinical responders | 33.3 | 50.0 | 0 | 0 | 50.0 | 0 | 0 | — |
| Clinical non-responders | 0 | 0 | 0 | 0 | — | 0 | 0 | — |
Collected over Treatment-emergent adverse events AEs (TEAEs): collected from the first dose of study drug through Week 52 plus 30 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-Blind Induction Phase: Placebo BID | 0/37 (0%) | 2/37 (5.4%) | 25/37 (67.6%) |
| Double-Blind Induction Phase: Upadacitinib 3 mg BID | 0/39 (0%) | 5/39 (12.8%) | 32/39 (82.1%) |
| Double-Blind Induction Phase: Upadacitinib 6 mg BID | 0/37 (0%) | 2/37 (5.4%) | 27/37 (73%) |
| Double Blind Induction Phase: 12 mg BID | 0/36 (0%) | 10/36 (27.8%) | 23/36 (63.9%) |
| Double Blind Induction Phase: 24 mg BID | 0/36 (0%) | 3/36 (8.3%) | 28/36 (77.8%) |
| Double Blind Induction Phase: 24 mg QD | 0/35 (0%) | 7/35 (20%) | 25/35 (71.4%) |
| Double Blind Extension Phase: 3 mg BID | 0/60 (0%) | 18/60 (30%) | 31/60 (51.7%) |
| Double Blind Extension Phase: 6 mg BID | 0/23 (0%) | 2/23 (8.7%) | 9/23 (39.1%) |
| Double Blind Extension 12 mg BID | 0/59 (0%) | 5/59 (8.5%) | 35/59 (59.3%) |
| Double Blind Extension 24 mg QD | 0/36 (0%) | 5/36 (13.9%) | 14/36 (38.9%) |
| Open Label Extension Subjects Never Received OL 24 mg BID | 0/33 (0%) | 11/33 (33.3%) | 8/33 (24.2%) |
| Open Label Extension Subjects Received OL 24 mg BID | 0/27 (0%) | 4/27 (14.8%) | 17/27 (63%) |
| Event | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: 12 mg BID | Double Blind Induction Phase: 24 mg BID | Double Blind Induction Phase: 24 mg QD | Double Blind Extension Phase: 3 mg BID | Double Blind Extension Phase: 6 mg BID | Double Blind Extension 12 mg BID | Double Blind Extension 24 mg QD | Open Label Extension Subjects Never Received OL 24 mg BID | Open Label Extension Subjects Received OL 24 mg BID |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CROHN'S DISEASEGastrointestinal disorders | 1/37 | 2/39 | 2/37 | 1/36 | 2/36 | 0/35 | 7/60 | 0/23 | 2/59 | 4/36 | 7/33 | 3/27 |
| SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders | 0/37 | 0/39 | 0/37 | 1/36 | 0/36 | 2/35 | 2/60 | 0/23 | 1/59 | 0/36 | 1/33 | 0/27 |
| ABDOMINAL PAINGastrointestinal disorders | 0/37 | 0/39 | 0/37 | 0/36 | 0/36 | 0/35 | 0/60 | 0/23 | 1/59 | 2/36 | 1/33 | 0/27 |
| CHEST PAINGeneral disorders | 0/37 | 0/39 | 0/37 | 0/36 | 0/36 | 0/35 | 0/60 | 1/23 | 0/59 | 0/36 | 0/33 | 0/27 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 0/37 | 0/39 | 0/37 | 0/36 | 0/36 | 0/35 | 1/60 | 1/23 | 0/59 | 0/36 | 0/33 | 0/27 |
| ABDOMINAL ABSCESSInfections and infestations | 0/37 | 0/39 | 0/37 | 0/36 | 0/36 | 0/35 | 1/60 | 0/23 | 1/59 | 0/36 | 0/33 | 1/27 |
| NEPHROLITHIASISRenal and urinary disorders | 0/37 | 0/39 | 0/37 | 1/36 | 0/36 | 0/35 | 0/60 | 0/23 | 0/59 | 0/36 | 0/33 | 1/27 |
| SINUS BRADYCARDIACardiac disorders | 0/37 | 0/39 | 0/37 | 0/36 | 0/36 | 0/35 | 0/60 | 0/23 | 0/59 | 0/36 | 1/33 | 0/27 |
| FISTULA OF SMALL INTESTINEGastrointestinal disorders | 0/37 | 0/39 | 0/37 | 0/36 | 0/36 | 0/35 | 0/60 | 0/23 | 0/59 | 0/36 | 1/33 | 0/27 |
| INTESTINAL STENOSISGastrointestinal disorders | 0/37 | 0/39 | 0/37 | 0/36 | 0/36 | 0/35 | 1/60 | 0/23 | 0/59 | 0/36 | 1/33 | 0/27 |
| Event | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: 12 mg BID | Double Blind Induction Phase: 24 mg BID | Double Blind Induction Phase: 24 mg QD | Double Blind Extension Phase: 3 mg BID | Double Blind Extension Phase: 6 mg BID | Double Blind Extension 12 mg BID | Double Blind Extension 24 mg QD | Open Label Extension Subjects Never Received OL 24 mg BID | Open Label Extension Subjects Received OL 24 mg BID |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HEADACHENervous system disorders | 3/37 | 7/39 | 7/37 | 3/36 | 8/36 | 5/35 | 0/60 | 1/23 | 5/59 | 1/36 | 0/33 | 0/27 |
| FATIGUEGeneral disorders | 3/37 | 8/39 | 2/37 | 2/36 | 4/36 | 2/35 | 2/60 | 1/23 | 2/59 | 2/36 | 0/33 | 0/27 |
| CROHN'S DISEASEGastrointestinal disorders | 6/37 | 6/39 | 4/37 | 7/36 | 3/36 | 2/35 | 6/60 | 2/23 | 6/59 | 2/36 | 2/33 | 3/27 |
| ABDOMINAL PAINGastrointestinal disorders | 0/37 | 5/39 | 2/37 | 6/36 | 2/36 | 5/35 | 4/60 | 0/23 | 1/59 | 0/36 | 0/33 | 0/27 |
| URINARY TRACT INFECTIONInfections and infestations | 2/37 | 1/39 | 4/37 | 0/36 | 5/36 | 2/35 | 4/60 | 1/23 | 5/59 | 0/36 | 0/33 | 0/27 |
| PYREXIAGeneral disorders | 3/37 | 5/39 | 0/37 | 2/36 | 1/36 | 1/35 | 1/60 | 0/23 | 3/59 | 1/36 | 0/33 | 0/27 |
| VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 1/37 | 4/39 | 4/37 | 4/36 | 3/36 | 2/35 | 5/60 | 1/23 | 7/59 | 2/36 | 2/33 | 3/27 |
| VOMITINGGastrointestinal disorders | 1/37 | 4/39 | 1/37 | 3/36 | 3/36 | 1/35 | 1/60 | 0/23 | 3/59 | 1/36 | 1/33 | 3/27 |
| BRONCHITISInfections and infestations | 0/37 | 0/39 | 0/37 | 0/36 | 0/36 | 0/35 | 0/60 | 0/23 | 0/59 | 0/36 | 0/33 | 3/27 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 2/37 | 2/39 | 2/37 | 4/36 | 4/36 | 1/35 | 3/60 | 1/23 | 4/59 | 2/36 | 0/33 | 2/27 |
| Age, Continuous(years) | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD | Total |
|---|---|---|---|---|---|---|---|
| Mean | 40.5 ± 12.14 | 39.7 ± 14.03 | 40.5 ± 13.41 | 40.8 ± 15.18 | 42.5 ± 10.02 | 40.2 ± 12.60 | 40.7 ± 12.90 |
| Sex: Female, Male(Participants) | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD | Total |
|---|---|---|---|---|---|---|---|
| Female | 24 | 19 | 21 | 17 | 25 | 19 | 125 |
| Male | 13 | 20 | 16 | 19 | 11 | 16 | 95 |
| High-sensitivity C-reactive protein (hsCRP)(mg/L) | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD | Total |
|---|---|---|---|---|---|---|---|
| Mean | 20.8 ± 34.29 | 23.6 ± 51.43 | 17.9 ± 17.92 | 26.9 ± 28.86 | 17.1 ± 26.49 | 17.1 ± 20.83 | 20.6 ± 32.11 |
| Fecal Calprotectin(mcg/g) | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD | Total |
|---|---|---|---|---|---|---|---|
| Mean | 1734.7 ± 2444.07 | 1925.9 ± 2804.07 | 2128.5 ± 1978.73 | 2067.9 ± 2250.97 | 2074.8 ± 2324.15 | 1808.7 ± 2548.11 | 1960.8 ± 2371.86 |
| Inflammatory Bowel Disease Questionnaire (IBDQ)(units on a scale) | Double-Blind Induction Phase: Placebo BID | Double-Blind Induction Phase: Upadacitinib 3 mg BID | Double-Blind Induction Phase: Upadacitinib 6 mg BID | Double Blind Induction Phase: Upadacitinib 12 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg BID | Double Blind Induction Phase: Upadacitinib 24 mg QD | Total |
|---|---|---|---|---|---|---|---|
| Mean | 118.0 ± 28.45 | 115.2 ± 27.48 | 113.7 ± 25.86 | 115.2 ± 36.05 | 113.8 ± 35.97 | 120.7 ± 36.25 | 116.1 ± 31.60 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Mar 2015 to primary completion in Nov 2016, 20 months.
Results were first posted in Aug 2023, 6 years 8 months after primary completion. A results delay was requested in Nov 2017.
Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 20 months is below that.
Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib